Treating cognitive impairment in depression: An unmet need

The Lancet Psychiatry

Volumn 3, Issue 5, 2016, Pages 392-393

  Keefe, Richard S E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; LISDEXAMFETAMINE; VORTIOXETINE;

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONSENSUS; DISABILITY; EXECUTIVE FUNCTION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HUMAN; MAJOR DEPRESSION; NOTE; RECALL; SCHIZOPHRENIA; TASK PERFORMANCE; WORKING MEMORY; DEPRESSION; LONGITUDINAL STUDY;

ANTIDEPRESSIVE AGENTS; COGNITIVE DYSFUNCTION; DEPRESSION; DEPRESSIVE DISORDER; HUMANS; LONGITUDINAL STUDIES;

EID: 84961231118     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(16)00095-X     Document Type: Note

References (12)

1. Rock PL, Roiser JP, Riedel WJ, Blackwell AD Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med 2014, 44:2029-2040.
2. Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 2006, 67:1754-1759.
3. Evans VC, Iverson GL, Yatham LN, Lam RW The relationship between neurocognitive and psychosocial functioning in major depressive disorder: a systematic review. J Clin Psychiatry 2014, 75:1359-1370.
4. Shilyansky C, Williams LM, Gyurak A, Harris A, Usherwood T, Etkin A Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study. Lancet Psychiatry 2016, published online March 16. http://dx.doi.org/10.1016/S2215-0366(16)00012-2.
5. Keefe RS, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. J Clin Psychiatry 2014, 75:864-876.
6. Bowie CR, Gupta M, Holshausen K, Jokic R, Best M, Milev R Cognitive remediation for treatment-resistant depression: effects on cognition and functioning and the role of online homework. J Nerv Ment Dis 2013, 201:680-685.
7. Madhoo M, Keefe RS, Roth RM, et al. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology 2014, 39:1388-1398.
8. Katona C, Hansen T, Olsen CK A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012, 27:215-223.
9. McIntyre RS, Lophaven S, Olsen CK A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacology 2014, 17:1557-1567.
10. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 2015, 40:2025-2037.
11. Enabling discovery, development, and translation of treatments for cognitive dysfunction in depression: workshop summary Institute of Medicine, (accessed Feb 15, 2016). http://iom.nationalacademies.org/Reports/2015/Enabling-Discovery-Development-Translation-of-Treatments-for-Cognitive-Dysfunction-in-Depression.aspx.
12. Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol 2013, 23:1373-1382.